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Mineralocorticoid receptor antagonists (MRA) have greatly impacted the management of patients 
with heart failure (HF). Both the European Society of Cardiology (ESC) and the American College of 
Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) practice 
guidelines now give a class I recommendation for patients with HF and reduced ejection fraction 
(HFrEF) across the symptom spectrum with relatively preserved renal function to reduce mortality 
and morbidity risk, and a class II recommendation for those with HF and preserved ejection fraction 
(HFpEF) to decrease risk of hospitalization.1  
Important clinical trials have shaped the evidence behind these recommendations. In 
patients with HFrEF, MRAs have been studied by three major outcomes trials: the Randomized 
Aldactone Evaluation Study (RALES)2, the Eplerenone Post-Acute Myocardial Infarction Heart Failure 
Efficacy and Survival Study (EPHESUS)3, and the Eplerenone in Mild Patients Hospitalization and 
Survival Study in Heart Failure (EMPHASIS-HF)4. The RALES trial evaluated spironolactone in patients 
with New York Heart Association (NYHA) class III and IV symptoms. Two subsequent studies, 
EPHESUS and EMPHASIS-HF, evaluated eplerenone in HF patients in the days following acute 
myocardial infarction and in patients with mild symptoms (NYHA functional class II), respectively. All 
three studies demonstrated significant risk reduction for morbidity and cardiovascular mortality with 
MRA therapy in addition to standard care. In patients with HFpEF, one key trial, the Treatment of 
Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT),5 found no 
reduction in risk of cardiovascular mortality but did show a reduced risk for HF-related hospitalization 
in the spironolactone group as compared to placebo; additionally there were major concerns raised 
regarding the trial conduct and regional differences in this trial.  
Notably, all four randomized clinical trials excluded patients with serum potassium levels >5 
mmol/L and patients with renal impairment, as measured by either serum creatinine >221 μmol/L (2.5 
mg/dL) or estimated glomerular filtration rate <30 mL/min (Table 1). These exclusion criteria were 
selected to curb the potential for harm related to an increased risk of hyperkalemia in patients with 
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HF, a risk that is further heightened by other comorbid diseases like chronic kidney disease (CKD) and 
background pharmacologic therapies including beta-blockers and those modulating angiotensin II.6, 7 
The clinical implications of this risk were fully realized by a report by Juurlink et al.8 that 
demonstrated an increase in both prescription of spironolactone and of hyperkalemia-associated 
morbidity and mortality following publication of RALES. Based on these concerns, both the ESC and 
the ACC/AHA/HFSA guidelines advise caution in initiating MRA therapy, limiting it to patients with 
serum potassium levels of <5 mmol/L and in those with relatively preserved renal function.  
While there is clarity in terms of the eligibility criteria for clinical trials with MRAs with regards 
to initiating therapy in clinical practice, the management of patients who develop hyperkalemia 
subsequent to the initiation of therapy remains uncertain and inconsistent. Current ESC as well as 
ACC/AHA/HFSA guidance recommend continuation of MRAs with serum potassium levels ≤5.5 
mmol/L. If serum potassium >5.5 mmol/L, current recommendation is to halve the dose and closely 
monitor blood chemistry. If serum potassium is  >6.0 mmol/L, cessation of MRA therapy is advised 
(Table 2).1, 9, 10  
Since this guidance was first issued, subsequent studies have deepened our understanding of 
the risks associated with hyperkalemia in low risk patients as well as those with various comorbidities 
(Figure 1). Secondary analyses of RALES and EMPHASIS-HF trials showed that despite serum 
potassium levels >5.5 mmol/L, MRAs maintained their benefits, implicitly suggesting that perhaps the 
benefit of therapy was greater than the risks of mild hyperkalemia.11, 12 Recently, a growing body of 
observational evidence demonstrate a U-shaped relationship between potassium levels and 
mortality in patients with various morbidities including HF, hypertension, and myocardial infarction, 
where those with either hypo- or hyperkalemia fare worse. It is unclear as to how much of the 
outcomes are related to hyperkalemia itself, how much to progression of underlying disease due to 
sub-optimal therapy related to hyperkalemia, and how much to the underlying comorbidity burden 
that puts individuals at risk for hyperkalemia.  
In 2012, a cohort study demonstrated patients with serum potassium >5 mmol/L as well as 
those with even high-normal potassium levels had worse outcomes, with an ideal serum potassium 
level ranging between 3.5-4.5 mmol/L.13 Subsequent data from the Danish National registry further 
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attested to the U-shaped correlation between potassium level and mortality risk. In 2015, a study in 
patients receiving loop diuretics after their first episode of myocardial infarction identified a higher 
risk of mortality with serum potassium levels outside 3.9-4.5 mmol/L.14 Another report examined 
44,799 hypertensive patients, and found that serum potassium levels outside 4.1-4.7 mmol/L were 
associated with higher mortality.15 Recently, another study analyzed 19,549 patients with HF 
receiving treatment with both loop diuretics and angiotensin converting enzyme inhibitors or 
angiotensin-II receptor blockers and found potassium <3.5 mmol/L and >5 mmol/L to be associated 
with higher mortality. Levels of potassium even within the lower (3.5-4.1 mmol/L) and upper (4.8-5.0 
mmol/L) normal range were associated with higher 90-day mortality risk.16 
Another study by Núñez et al. monitored potassium levels during follow-up encounters in 
patients after HF hospitalization and found similar U-shaped risk. Interestingly, persistently elevated 
potassium levels were associated with higher mortality risk, and normalization of these imbalances 
was independently associated with lowered mortality risk.17 A recent report by Collins et al. also 
demonstrated a U-shaped association between serum potassium and mortality risk, but noted that 
this mortality risk was significantly greater in those with comorbid HF, CKD or diabetes mellitus 
(DM).18 These reports propose that better outcomes are associated with a more limited range of 
potassium levels than previously believed, even extending into a presumed normal range. It is 
important to note that some studies do not demonstrate the same heightened mortality risk with 
increased serum potassium levels. For example, Hoss et al. analyzed a cohort of 6073 patients with 
chronic HF and found those with “high-normal” potassium levels (in the range of 5.0-5.5 mmol/L) to 
have better outcomes.19 Data regarding the safety of hyperkalemia is further limited in patients with 
acute HF. Tromp et al. analyzed combined data from two large cohorts and noted a linear association 
between potassium levels at admission and mortality, an association that was no longer apparent 
after multivariate adjustment.20 Another study by Khan et al. found no association between in-
hospital changes in potassium and mortality or hospitalization for HF.21 In patients with acute HF, 
some data analyses find a decrease in serum potassium levels during hospitalization of >15% to be 
associated with higher mortality risk.22 
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Although data remains limited, it still calls into question the current recommendation that 
MRA dose be halved with potassium levels >5.5 mmol/L and stopped only with levels >6.0 mmol/L 
since allowing patients with HF, CKD, DM, and especially those > 65 years of age with these 
comorbidities to remain at a serum potassium > 5.0 mmol/l if not on a MRA places them at increased 
risk of death. These data further support the need for closer long-term monitoring of serum 
potassium throughout MRA therapy, perhaps more frequently in those at increased risk of 
hyperkalemia than the current recommendations of every 4 months. Caution should also be 
exercised in patients with levels >5.5 mmol/L who are on an MRA, including those taking beta-
blockers or angiotensin II modulators and every attempt should be made to keep serum potassium 
levels ≤5 mmol/L in those patients not on a MRA. Finally, better therapies for long-term management 
of hyperkalemia to optimize HF management are urgently needed.23 
HF is a challenging chronic illness and suspending life-saving therapies puts this susceptible 
population at increased risk. MRAs are already underutilized in HFrEF. However, while appropriate 
use should be encouraged, clear guidelines to manage these patients on therapy also need to be 
developed and updated in light of these new data. In patients already initiated on MRA therapy, the 
challenge becomes attaining a fine balance between optimization of medications to prevent disease 
progression and minimizing risk of hyperkalemia-related adverse events. We must be cautious not to 
cause iatrogenic harm. Accruing evidence has questioned the safety not only of serum potassium 
levels >5 mmol/L but even potassium levels on the higher end of “normal,” especially in patients with 
HF, CKD and DM. The increased mortality risk associated with a high serum potassium level reflects 
multiple risks including ventricular fibrillation and other conduction abnormalities, comorbidity 
burden, and underutilization of optimal medical therapy. Of note, at any particular serum potassium 
level, other factors including an underlying pathophysiology, rate of change in potassium level, pH, 
and calcium concentration will all influence complication and mortality risk.  
These data support the need for reevaluation of guidelines, which currently suggest that 
serum potassium levels of up to 5.5 mmol/L can be monitored without intervention in patients with 
HF. Normokalemia may be a narrower range than previously recognized in patients with HF. Changes 
in guidelines are common as new data emerge, e.g. serum digoxin concentrations were considered 
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to be safe up to 2 ng/mL. However, subsequent data showed risk of digoxin-associated mortality at 
lower levels, leading to new guidelines recommendation to keep digoxin concentration <1.2 ng/mL.24 
Similar revision for MRA therapy and hyperkalemia is warranted. Emerging data calls for narrower 
ranges of acceptable potassium levels during MRA therapy in patients with HF, especially those with 
concomitant CKD and or DM > 65 years of age. Perhaps revised, more explicit guidelines for 
monitoring and intervening during MRA therapy for patients with HF will increase the safety of these 
agents and thus the utilization of this life-saving therapy.  
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Table 1: Eligibility criteria and management of hyperkalemia in randomized trials 
 
Clinical 
Trial Exclusion Criteria 
Dose Adjustments for Serum Potassium (K) 
(mmol/L) 
RALES2 Scr > 221 μmol/L (2.5 mg/dL), serum K > 5 mmol/L 
If K ≥ 5.5, decrease dose to 25 mg every other 
day (although investigator encouraged to 
initially adjust doses of concomitant 
medications) 
If K ≥ 6.0, withhold study medication 
EPHESUS3 Scr > 221 μmol/L (2.5 mg/dL), serum K > 5 mmol/L 
If K ≥ 5.5, decrease dose by 25 mg (and 
withhold if on lowest dose of 25 mg daily) 
If K ≥ 6.0, discontinue until K < 5.5 
EMPHASIS-
HF4 
eGFR < 30 mL/min, serum K > 5 
mmol/L 
For eGFR ≥ 50 mL/min: 
If K ≥ 5.5, decrease dose to 25 mg; If K ≥ 6.0, 
withhold dose, re-check K within 72 hours and 
resume if K < 5.0 
 
For eGFR 30-49 mL/min: 
If K ≥ 5.5, withhold dose and re-check within 
72 hours and resume if K < 5.0; If K ≥ 6.0, 
withhold and recheck K within 72 hours and 
resume if K < 5.0 
 
TOPCAT5 
eGFR < 30 mL/min, Scr ≥ 221 μmol/L 
(2.5 mg/dL), serum K ≥ 5.5 mmol/L in 
past 6 months, serum K ≥ 5 mmol/L in 
past 2 weeks 
If K ≥ 5.5, reduce drug by 15 mg (no 
uptitration beyond this level for remainder of 
study) 
If K ≥ 6.0, permanently discontinue study drug 
Abbreviations: eGFR, estimated glomerular filtration rate; K, potassium; MRA, mineralocorticoid 
receptor antagonist; Scr, serum creatinine 
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Table 2: Current guidelines for the initiation, monitoring, and management of hyperkalemia on 
MRA therapy. 
 




Serum K < 5.0 
mmol/L 
Scr < 221 μmol/L 
(2.5 mg/dL) in 
men, Scr < 176.8 
μmol/L (2.0 
mg/dL) in women 
(or eGFR > 30 
mL/min)  
 
Monitor Scr and serum K 72 hours-1 
week after initiation or dose increase 
of MRA, then monthly for first 3 
months, then 3-4 months thereafter  
 
If K 5.5-5.9 mmol/L, 
halve dose (or take 
every other day if at 
lowest dose)  
If K > 6.0 mmol/L, 
hold and reassess 
after 72 hours until K 
< 5.0 mmol/L  
ESC1 
 
Serum K < 5.0 
mmol/L 
Scr < 221 μmol/L 
(2.5 mg/dL) (or 
eGFR > 30 
mL/min) 
 
Monitor blood chemistry 1 and 4 
weeks after initiation/uptitration and 
at 8 and 12 weeks and 6, 9 and 12 
months. Thereafter, monitor every 4 
months.  
 
If K > 5.5 mmol/L or 
Scr > 221 μmol/L (2.5 
mg/dL), halve dose 
and monitor blood 
chemistry closely  
If K > 6.0 mmol/L or 
Scr > 309.4 μmol/L 
(3.5 mg/dL), stop 
MRA therapy 
immediately  
Abbreviations: eGFR, estimated glomerular filtration rate; K, potassium; Scr, serum creatinine; MRA, 
mineralocorticoid receptor antagonist; WRF, worsening renal function 
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